BACKGROUND: Peripartum cardiomyopathy (PPCM or PCMO) is a rare disease of unknown etiology, characterised by an acute onset of heart failure in women in the late stage of pregnancy or in the early months postpartum. OBJECTIVES: To assess the effectiveness and safety of any intervention for the care of women and/or their babies with a diagnosis of peripartum cardiomyopathy. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (27 July 2010) and the reference lists of identified studies. SELECTION CRITERIA: Randomised and quasi-randomised controlled trials of any intervention for treating peripartum cardiomyopathy. Such interventions include: drugs; cardiac monitoring and treatment; haemodynamic monitoring and treatments; supportive therapies and heart transplant. DATA COLLECTION AND ANALYSIS: Two authors independently assessed the studies for inclusion, assessed risk of bias and carried out data extraction. Data entry was checked. MAIN RESULTS: We identified and included one pilot study, involving 20 women, undertaken in South Africa. Women were diagnosed postnatally and included in the study within 24 hours of diagnosis. AUTHORS' CONCLUSIONS: There are insufficient data to draw any firm conclusions. Treatment with bromocriptine appears promising, although women would be unable to breastfeed due to suppression of lactation.
BACKGROUND:Peripartum cardiomyopathy (PPCM or PCMO) is a rare disease of unknown etiology, characterised by an acute onset of heart failure in women in the late stage of pregnancy or in the early months postpartum. OBJECTIVES: To assess the effectiveness and safety of any intervention for the care of women and/or their babies with a diagnosis of peripartum cardiomyopathy. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (27 July 2010) and the reference lists of identified studies. SELECTION CRITERIA: Randomised and quasi-randomised controlled trials of any intervention for treating peripartum cardiomyopathy. Such interventions include: drugs; cardiac monitoring and treatment; haemodynamic monitoring and treatments; supportive therapies and heart transplant. DATA COLLECTION AND ANALYSIS: Two authors independently assessed the studies for inclusion, assessed risk of bias and carried out data extraction. Data entry was checked. MAIN RESULTS: We identified and included one pilot study, involving 20 women, undertaken in South Africa. Women were diagnosed postnatally and included in the study within 24 hours of diagnosis. AUTHORS' CONCLUSIONS: There are insufficient data to draw any firm conclusions. Treatment with bromocriptine appears promising, although women would be unable to breastfeed due to suppression of lactation.
Authors: James D Fett; Robert D Carraway; Duane L Dowell; Mary Etta King; Ronald Pierre Journal: Am J Obstet Gynecol Date: 2002-05 Impact factor: 8.661
Authors: B Bozkurt; F S Villaneuva; R Holubkov; T Tokarczyk; R J Alvarez; G A MacGowan; S Murali; W D Rosenblum; A M Feldman; D M McNamara Journal: J Am Coll Cardiol Date: 1999-07 Impact factor: 24.094
Authors: J W Mason; J B O'Connell; A Herskowitz; N R Rose; B M McManus; M E Billingham; T E Moon Journal: N Engl J Med Date: 1995-08-03 Impact factor: 91.245
Authors: J G F Cleland; K Swedberg; F Follath; M Komajda; A Cohen-Solal; J C Aguilar; R Dietz; A Gavazzi; R Hobbs; J Korewicki; H C Madeira; V S Moiseyev; I Preda; W H van Gilst; J Widimsky; N Freemantle; Joanne Eastaugh; J Mason Journal: Eur Heart J Date: 2003-03 Impact factor: 29.983
Authors: J B O'Connell; M R Costanzo-Nordin; R Subramanian; J A Robinson; D E Wallis; P J Scanlon; R M Gunnar Journal: J Am Coll Cardiol Date: 1986-07 Impact factor: 24.094